683 Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

683 Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-176,030	Closed	-$6.77M	–	253
2025 Q3	$6.77M	Hold	176,030	–	–	0.35%	59
2025 Q2	$3.63M	Buy	+176,030	New	+$4.16M	0.24%	87

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

683 Capital Management's TVRD Position: Q4 2025 in Review

683 Capital Management sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 176,030 shares — an estimated $6.77M sold.

683 Capital Management first reported a position in TVRD in Q2 2025 and held it in 2 quarters. The position peaked at $6.77M in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

683 Capital Management reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
683 Capital Management sold 176,030 Tvardi Therapeutics shares in Q4 2025, an estimated $6.77M.
683 Capital Management first reported a position in Tvardi Therapeutics in Q2 2025 and held it in 2 quarters.
683 Capital Management's Tvardi Therapeutics position peaked at $6.77M in Q3 2025.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on 683 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.